DE60321443D1 - Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung - Google Patents

Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung

Info

Publication number
DE60321443D1
DE60321443D1 DE60321443T DE60321443T DE60321443D1 DE 60321443 D1 DE60321443 D1 DE 60321443D1 DE 60321443 T DE60321443 T DE 60321443T DE 60321443 T DE60321443 T DE 60321443T DE 60321443 D1 DE60321443 D1 DE 60321443D1
Authority
DE
Germany
Prior art keywords
prophylactic
screening method
therapeutic substance
kidney disease
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60321443T
Other languages
English (en)
Inventor
Masakuni Noda
Takanori Matsuo
Hiroko Tsuge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE60321443D1 publication Critical patent/DE60321443D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60321443T 2002-01-10 2003-01-09 Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung Expired - Lifetime DE60321443D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002003769 2002-01-10
PCT/JP2003/000111 WO2003060516A1 (fr) 2002-01-10 2003-01-09 Methode de criblage

Publications (1)

Publication Number Publication Date
DE60321443D1 true DE60321443D1 (de) 2008-07-17

Family

ID=19190917

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60321443T Expired - Lifetime DE60321443D1 (de) 2002-01-10 2003-01-09 Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung

Country Status (6)

Country Link
US (1) US20050069948A1 (de)
EP (1) EP1467207B1 (de)
AT (1) ATE397753T1 (de)
AU (1) AU2003202489A1 (de)
DE (1) DE60321443D1 (de)
WO (1) WO2003060516A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1560025A3 (de) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Marker spezifisch für Diabetes
US7763441B2 (en) 2006-03-13 2010-07-27 Wyeth Modulators of gluconeogenesis
CN102816214B (zh) * 2012-07-27 2014-08-13 中国人民解放军军事医学科学院生物工程研究所 乙型肝炎病毒HBx基因的人工转录因子及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206152A (en) * 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5763209A (en) * 1988-09-26 1998-06-09 Arch Development Corporation Methods and materials relating to the functional domains of DNA binding proteins
AUPN855496A0 (en) * 1996-03-07 1996-04-04 Unisearch Limited Prevention of proliferation of vascular cells
EE200000790A (et) * 1998-06-02 2002-04-15 Glaxo Group Limited Geeniteraapia meetod
US6008048A (en) * 1998-12-04 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of EGR-1 expression
AU6088300A (en) * 1999-07-12 2001-01-30 Gene Logic, Inc. Modulation of egr-1 and egr-2 in heart disease
AUPQ367699A0 (en) * 1999-10-26 1999-11-18 Unisearch Limited Treatment of cancer
EP1239039A4 (de) * 1999-12-17 2004-05-06 Takeda Chemical Industries Ltd Neues polypeptid und dafür kodierende dna
AU2001251242A1 (en) * 2000-03-31 2001-10-15 Brown University Reseach Foundation Methods and compositions for regulating memory consolidation

Also Published As

Publication number Publication date
US20050069948A1 (en) 2005-03-31
EP1467207A1 (de) 2004-10-13
WO2003060516A1 (fr) 2003-07-24
EP1467207A4 (de) 2006-06-07
ATE397753T1 (de) 2008-06-15
EP1467207B1 (de) 2008-06-04
AU2003202489A1 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
DE60333963D1 (de) Zytokin Ligand zur Behandlung von Asthma und Atemwegsüberreaktivität
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
DK1645631T3 (da) Neisseria antigener og præparater
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
DK1521774T3 (da) Trunkerede Tau-proteiner
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
ATE392430T1 (de) Verfahren zur herstellung von dipeptiden
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE60237791D1 (de) Zytokinproteinfamilie
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
ATE397753T1 (de) Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung
ITTO20000674A0 (it) Composizioni a base di aminoacidi, atte al trattamento dell'insufficienza cardiaca.
DE60226253D1 (de) Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
ATE452903T1 (de) Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
EP1666880A4 (de) Screening-verfahren
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
ATE556135T1 (de) Neues protein
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
ATE465175T1 (de) Neuer proteinkomplex und anwendungen davon
WO2003022300A1 (fr) Remedes prophylactiques et curatifs contre les maladies des os et des articulations
EP1566386A4 (de) Gen in zusammenhang mit haarausfall, das davon kodierte polypeptid und anwendungen dafür
WO2003070770A3 (en) Engineered human kunitz-type protease inhibitor
DE60135971D1 (de) Mit wt1 interagierendes protein, wtip
WO2002000834A3 (fr) Nouveau polypeptide, proteine phosphatase humaine 9.68, et polynucleotide codant ce polypeptide

Legal Events

Date Code Title Description
8364 No opposition during term of opposition